Navigation Links
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Date:7/27/2009

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study.

The data also showed that dirucotide was generally well tolerated. There were no unexpected safety or tolerability issues. The most common side effect reported was injection site reaction. More details of the MAESTRO-01 study results are expected to be presented at a medical conference later this year.

Lilly and BioMS also announced they would discontinue ongoing clinical trials - including MAESTRO-02 and MAESTRO-03 - and review the available data from these studies. MAESTRO-02 is an open-label follow-on study to MAESTRO-01. MAESTRO-03 is a 510-patient U.S. Phase III clinical trial designed to evaluate dirucotide for the treatment of SPMS that completed enrollment in August 2008. Lilly and BioMS will inform regulatory agencies and provide instructions to investigators outlining the process for discontinuing the studies. Patients involved in studies who have questions should contact their study investigator.

"The MAESTRO-01 study was well designed and executed, and we believe these data, while disappointing, are very instructive for us and for the larger MS community," said John Hayes, vice president of Lilly Research Laboratories. "We look forward to further conversations with BioMS Medical about this project."

"We are obviously disappointed b
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
2. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
3. MADIT-CRT Trial Meets Primary Endpoint
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
6. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... entered into a definitive distribution agreement with Patterson Veterinary ... and promote the full line of Abaxis veterinary products ...
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... 9, 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and ... 767905/014 and,provided an update on the clinical ... Phase 3, double blind, placebo-controlled (12,month) study, ... and,tolerability of alvimopan 0.5 mg twice daily ...
... Educate on Good,Diabetes Management and How to Reduce ... 10, 2007 /PRNewswire/ -- A first-of-its-kind,report looking at ... shows that an estimated three out of five ... least one of the other,serious health problems commonly ...
Cached Medicine Technology:GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
(Date:10/2/2014)... October 02, 2014 Recently, BambooIndustry.com, a ... its new collection of bamboo floors . What’s ... a lot of its products at the moment. According ... up to 26 percent off. The promotion will be ... floors ( http://www.bambooindustry.com ) are all made by qualified ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product ... great appreciation from the global customers in the past ... make more excellent items. All its online workers are ... clients. , The company has recently added a ... website. Furthermore, the company’s marketing specialist has announced that ...
(Date:10/2/2014)... with autism are more sedentary than those without the ... a small study suggests. Researchers tested the fitness ... and some without. Children with autism averaged 50 fewer ... more minutes each day sitting than those without autism. ... strength, but had similar body-mass index (a measurement of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... research study published today in the Journal of ... older than 50 years with moderate or severe chronic ... Researchers from the University of Melbourne randomly assigned 282 ... to no acupuncture or sham or pretend laser treatment. ... participants and acupuncturists blinded to laser and sham (inactive) ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... VICTORVILLE, Calif., Feb. 5 Dr. Richard Merkin ... Senior,Valentine,s Day Luncheon. They will host this special luncheon ... Victorville Senior Hall., The event is open to ... down,meal from Carino,s Italian Grill and entertainment by the ...
... more likely than nonsmokers to report lack of restful slumber, ... are four times more likely to feel tired when they ... than nonsmokers do, a new study finds. , This may ... contribute to sleep disturbances, suggest the study authors, whose report ...
... finding turned out to be a clue leading researchers ... to propose a new treatment approach for Niemann-Pick disease, ... the genetic defect in Niemann-Pick disease, the researchers suggest ... through the cell,s quality control machinery. And they believe ...
... Agency has finalised an agreement with an ESA-led ... which contributes to the premature deaths of hundreds ... agreement, the European Environment Agency (EEA) will use ... with surface measurements from 29 European countries to ...
... 5 Keystone Human Services (KHS),is pleased ... Inc., a privately,owned, Pennsylvania based for-profit agency ... autism for 35 years. Impact,Systems, Inc., serving ... will become an important component of,Keystone,s regional ...
Cached Medicine News:Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Smokers Sleep Less Soundly 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Satellite data to deliver 'state-of-the-art' air quality information 2Health News:Keystone Human Services Acquires Impact Systems, Inc. 2
Straight shafts with 1 x 2 teeth. Serrated handle, non-magnetic and polished finish....
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: